Frank C. Richardson

TL;DR: Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.

TL;DR: The feasibility of a multicenter biomarker-driven study was demonstrated, but neither treatment arms exceeded historical controls and this study does not support combined chemotherapy and erlotinib in first-line treatment of EGFR-selected advanced NSCLC.

TL;DR: Investigation of the relationships between the potency observed in cell-based assays in vitro, the plasma exposure levels achieved following oral dosing, the time course of target inhibition in vivo, and antitumor activity of OSI-930 in tumor xenograft models suggest that antitumors activity of the novel inhibitor of the receptor tyrosine kinases Kit and kinase insert domain receptor is observed at dose levels that maintain a significant level of inhibition of the molecular targets for a prolonged period.

TL;DR: Altered changes in Tk KO mice indicate that the pyrimidine nucleotide salvage pathway is indispensable in vivo, and suggests an abnormal immune system.

TL;DR: E-Cadherin and vimentin are biomarkers worthy of additional study as predictive markers of outcome of erlotinib therapy.